WASHINGTON, March 29, 2011 /PRNewswire/ -- MedImmune announced today it will present a total of 11 abstracts at the 45th National Immunization Conference (NIC) at the Washington Hilton in Washington, DC, March 28 - 31, 2011. These abstracts advance the body of existing data and knowledge surrounding influenza prevention and trends in vaccination, highlighting MedImmune's strong leadership in patient health in various medical settings.
"MedImmune is pleased to announce new research on school-located influenza vaccination programs and use of influenza vaccines in special populations," said William Martone, MD, senior vice president of medical and scientific affairs at MedImmune. "We believe the data being presented at NIC will help the medical community explore innovative ways to prevent influenza in and outside of the medical home."
MedImmune abstracts to be presented at NIC on school-located influenza vaccination programs include:
MedImmune abstracts to be presented at NIC on influenza vaccines in specific populations and/or groups include:
Additional information about the 2011 NIC conference can be found at http://www.cdc.gov/vaccines/events/nic/default.htm.
MedImmune, the global biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.
Copyright©2010 PR Newswire.
All rights reserved